☰

cached image

Darell D. Bigner, M.D., Ph.D. - Publications

Affiliations: 
Pathology and Surgery Duke University, Durham, NC 
Area:
Neuro-Oncology
Website:
http://pathology.mc.duke.edu/neuropath/np_faculty_dbigner.htm
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Sun MA, Yang R, Liu H, Wang W, Song X, Hu B, Reynolds N, Roso K, Chen LH, Greer PK, Keir ST, McLendon RE, Cheng SY, Bigner DD, Ashley DM, et al. Repurposing Clemastine to Target Glioblastoma Cell Stemness. Cancers. 15. PMID 37760589 DOI: 10.3390/cancers15184619  0.473
2023 Thompson EM, Landi D, Brown MC, Friedman HS, McLendon R, Herndon JE, Buckley E, Bolognesi DP, Lipp E, Schroeder K, Becher OJ, Friedman AH, McKay Z, Walter A, Threatt S, ... ... Bigner DD, et al. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. The Lancet. Child & Adolescent Health. PMID 37004712 DOI: 10.1016/S2352-4642(23)00031-7  0.476
2023 Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, ... ... Bigner DD, et al. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science Translational Medicine. 15: eabn5649. PMID 36753564 DOI: 10.1126/scitranslmed.abn5649  0.498
2021 Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, ... ... Bigner DD, et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications. 12: 352. PMID 33441554 DOI: 10.1038/s41467-020-20469-6  0.529
2020 Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nature Communications. 11: 524. PMID 31988324 DOI: 10.1038/S41467-019-13939-Z  0.335
2020 Desjardins A, Randazzo D, Chandramohan V, Peters KB, Johnson MO, Threatt S, Bullock CA, Herndon JE, Healy P, Lipp ES, Sampson JH, Friedman AH, Friedman HS, Ashley DM, Bigner DD. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Journal of Clinical Oncology. 38: 2566-2566. DOI: 10.1200/Jco.2020.38.15_Suppl.2566  0.318
2019 Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. Journal For Immunotherapy of Cancer. 7: 142. PMID 31142380 DOI: 10.1186/S40425-019-0614-0  0.359
2019 Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, ... ... Bigner DD, et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Research. PMID 31040154 DOI: 10.1158/0008-5472.Can-18-1010  0.505
2019 Yu X, Dobrikov M, Keir ST, Gromeier M, Pastan IH, Reisfeld R, Bigner DD, Chandramohan V. Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. Plos One. 14: e0210608. PMID 30625226 DOI: 10.1371/Journal.Pone.0210608  0.419
2019 Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology. 78: 57-64. PMID 30500933 DOI: 10.1093/Jnen/Nly110  0.523
2019 Desjardins A, Gromeier M, Herndon JE, Randazzo D, Threatt S, Lipp ES, Miller ES, Jackman J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Peters KB, Johnson MO, Sampson JH, ... ... Bigner DD, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial. Journal of Clinical Oncology. 37: 2060-2060. DOI: 10.1200/Jco.2019.37.15_Suppl.2060  0.362
2019 Gromeier M, Mosaheb M, Dobrikova E, Brown M, Bigner D, Ashley D. EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY Neuro-Oncology. 21: vi93-vi93. DOI: 10.1093/Neuonc/Noz175.382  0.363
2019 Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, ... ... Bigner D, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026  0.588
2019 Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Threatt S, Bullock C, Jackman J, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 21: vi6-vi6. DOI: 10.1093/Neuonc/Noz175.023  0.317
2018 Diplas BH, Liu H, Yang R, Hansen LJ, Zachem AL, Zhao F, Bigner DD, McLendon RE, Jiao Y, He Y, Waitkus MS, Yan H. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro-Oncology. PMID 30346624 DOI: 10.1093/Neuonc/Noy167  0.478
2018 Thompson EM, Landi D, Ashley D, Keir ST, Bigner D. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. Journal of Neuro-Oncology. PMID 30120661 DOI: 10.1007/S11060-018-2975-5  0.303
2018 Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, ... ... Bigner DD, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/Nejmoa1716435  0.561
2018 Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M. Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology. PMID 29878245 DOI: 10.1093/Jnen/Nly045  0.563
2018 Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, ... ... Bigner DD, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications. 9: 2087. PMID 29802247 DOI: 10.1038/S41467-018-04448-6  0.508
2018 Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy P, Herndon JE, McLendon RE, Keir ST, Archer GE, ... ... Bigner DD, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29703821 DOI: 10.1158/1078-0432.Ccr-17-0126  0.59
2018 Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of Neuro-Oncology. PMID 29564747 DOI: 10.1007/S11060-018-2832-6  0.378
2018 Woroniecka K, Chongsathidkiet P, Rhodin KE, Kemeny HR, Dechant CA, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson CC, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, ... Bigner DD, et al. T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29437767 DOI: 10.1158/1078-0432.Ccr-17-1846  0.313
2018 Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Abstract A79: Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of antigen-presenting cells and tumor antigen-specific CTLs Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A79  0.413
2018 Dombrowski S, Abou-Antoun T, Mansour A, Arar R, Movassaghi M, Murphy E, Banerjee S, Li X, Houghton P, Bigner D, Carcaboso AM, Rich J, Recinos V. Abstract A47: Inhibition of histone methyltransferase with novel epipolythiodioxopiperazines (ETP) alkaloids in pediatric high-grade glioma Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A47  0.341
2018 Landa K, Holl E, Brown M, Herndon J, Grimm L, Force J, Bigner D, Hwang S, Gromeier M, Nair S. Abstract LB-302: Oncolytic poliovirus-mediated inflammation and immunity in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-302  0.344
2018 Thompson E, Brown M, Dobrikova E, Ramaswamy V, Taylor M, McLendon R, Chandramohan V, Bigner D, Gromeier M. PDTM-46. POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA Neuro-Oncology. 20: vi213-vi213. DOI: 10.1093/Neuonc/Noy148.885  0.53
2018 Diplas B, Waitkus M, He X, Brosnan-Cashman J, Liu H, Chen L, Wang Z, Moure C, Killela P, Lipp E, Rodriguez F, Jiao Y, McLendon R, Bigner D, Meeker A, et al. GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA Neuro-Oncology. 20: vi112-vi112. DOI: 10.1093/Neuonc/Noy148.468  0.445
2018 Ashley D, Desjardins A, Gromeier M, Muscat A, Herndon J, Friedman A, Friedman H, McSherry F, Randazzo D, Peters K, Threatt S, Bullock C, Miller E, Boulton S, Lipp E, ... Bigner D, et al. ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES Neuro-Oncology. 20: vi7-vi7. DOI: 10.1093/Neuonc/Noy148.022  0.323
2018 Roskoski M, Gasinski D, Friedman H, Bigner D, Keir S. LGG-01. EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS Neuro-Oncology. 20: i104-i105. DOI: 10.1093/Neuonc/Noy059.345  0.371
2018 Gururangan S, Grant G, Driscoll T, Archer G, Herndon J, Friedman H, Kurtzberg J, Bigner D, Sampson J, Mitchell D. IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.343  0.348
2018 Landi D, Thompson E, McLendon R, Desjardins A, Chandramohan V, Ashley D, Bigner D. IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN Neuro-Oncology. 20: i103-i103. DOI: 10.1093/Neuonc/Noy059.337  0.546
2017 Di C, Mladkova N, Lin J, Fee B, Rivas M, Chunsheng K, Bigner D, Adamson DC. AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival. International Journal of Oncology. PMID 29115565 DOI: 10.3892/Ijo.2017.4184  0.444
2017 Xu C, Liu X, Geng Y, Bai Q, Pan C, Sun Y, Chen X, Yu H, Wu Y, Zhang P, Wu W, Wang Y, Wu Z, Zhang J, Wang Z, ... ... Bigner D, et al. Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget. 8: 76644-76655. PMID 29100338 DOI: 10.18632/Oncotarget.19656  0.417
2017 Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojeic I, McLendon RE, Friedman HS, He Y, ... Bigner DD, et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H) induced metabolic liabilities. Cancer Research. PMID 29097607 DOI: 10.1158/0008-5472.Can-17-1352  0.545
2017 Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Bigner DD, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.Can-17-0469  0.527
2017 Yu X, Qu L, Bigner DD, Chandramohan V. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display. Protein Engineering, Design & Selection : Peds. 1-9. PMID 28981720 DOI: 10.1093/Protein/Gzx038  0.379
2017 Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Research. PMID 28939681 DOI: 10.1158/0008-5472.Can-17-1018  0.531
2017 Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Science Translational Medicine. 9. PMID 28931654 DOI: 10.1126/Scitranslmed.Aan4220  0.381
2017 Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Archives of Pathology & Laboratory Medicine. PMID 28829151 DOI: 10.5858/Arpa.2016-0580-Oa  0.546
2017 Xu C, Liu X, Geng Y, Bai Q, Pan C, Sun Y, Chen X, Yu H, Wu Y, Zhang P, Wu W, Wang Y, Wu Z, Zhang J, Wang Z, ... ... Bigner D, et al. Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget. PMID 28775236 DOI: 10.18632/oncotarget.19656  0.301
2017 Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1898-1909. PMID 28411277 DOI: 10.1158/1078-0432.Ccr-16-2057  0.54
2017 Thompson EM, Keir ST, Venkatraman T, Lascola C, Yeom KW, Nixon AB, Liu Y, Picard D, Remke M, Bigner DD, Ramaswamy V, Taylor MD. The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. Neuro-Oncology. PMID 28379574 DOI: 10.1093/Neuonc/Nox033  0.304
2017 Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, et al. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research : McR. PMID 28148827 DOI: 10.1158/1541-7786.Mcr-16-0485  0.587
2017 Yu X, Keir ST, Szafranski S, Clayton S, Pastan I, Bigner DD, Chandramohan V. Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4. Journal of Clinical Oncology. 35: 74-74. DOI: 10.1200/Jco.2017.35.7_Suppl.74  0.384
2017 Bao X, Keir ST, Nair SK, Pastan I, Bigner DD, Chandramohan V. A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors. Journal of Clinical Oncology. 35: 102-102. DOI: 10.1200/Jco.2017.35.7_Suppl.102  0.415
2017 Desjardins A, Sampson JH, Vlahovic G, Peters KB, Randazzo D, Threatt S, Herndon JE, Bullock CA, Miller ES, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, ... Bigner DD, et al. Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG). Journal of Clinical Oncology. 35: e13533-e13533. DOI: 10.1200/Jco.2017.35.15_Suppl.E13533  0.352
2016 Bao X, Pastan I, Bigner DD, Chandramohan V. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors & Clinical Investigation. 3. PMID 28286803 DOI: 10.14800/Rci.1430  0.433
2016 Yu X, Pegram CN, Bigner DD, Chandramohan V. Development and Validation of a Cell-Based Fluorescent Method for Measuring Antibody Affinity. Journal of Immunological Methods. PMID 28024998 DOI: 10.1016/J.Jim.2016.12.004  0.308
2016 Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. Applied Microbiology and Biotechnology. PMID 28013405 DOI: 10.1007/S00253-016-8063-X  0.304
2016 Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget. PMID 27806313 DOI: 10.18632/Oncotarget.12975  0.373
2016 Li F, Liu X, Sampson JH, Bigner DD, Li CY. Rapid reprogramming of primary human astrocytes into potent tumor initiating cells with defined genetic factors. Cancer Research. PMID 27364552 DOI: 10.1158/0008-5472.Can-16-0171  0.385
2016 Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet. Oncology. PMID 26976201 DOI: 10.1016/S1470-2045(15)00581-1  0.473
2016 Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, ... ... Bigner DD, et al. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunology Research. PMID 26822025 DOI: 10.1158/2326-6066.Cir-15-0060  0.434
2016 Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, Wang Q, McLendon RE, Friedman AH, Keir ST, Bigner DD, et al. MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell. 29: 49-60. PMID 26766590 DOI: 10.1016/J.Ccell.2015.12.005  0.398
2016 Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Investigational New Drugs. PMID 26728879 DOI: 10.1007/S10637-015-0318-3  0.491
2016 Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls. Journal of Clinical Oncology. 34: 2061-2061. DOI: 10.1200/Jco.2016.34.15_Suppl.2061  0.41
2016 Brown MC, Holl EK, Boczkowski D, Bigner DD, Gromeier M, Nair SK. Abstract A157: Oncolytic poliovirus mediated immune events Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A157  0.415
2016 Gedeon PC, Schaller TH, Suryadevara CM, Choi BD, Reap EA, Archer GE, Sanchez-Perez L, Bigner DD, Sampson JH. IMST-45. A FULLY-HUMAN EGFRvIII-TARGETED BISPECIFIC ANTIBODY REDIRECTS HUMAN T CELLS TO SPECIFICALLY LYSE MALIGNANT GLIOMA Neuro-Oncology. 18: vi96-vi96. DOI: 10.1093/Neuonc/Now212.401  0.325
2016 Desjardins A, Randazzo D, Chandramohan V, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, Healy P, Lipp E, Friedman A, Friedman H, Bigner D. ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 18: vi21-vi22. DOI: 10.1093/Neuonc/Now212.083  0.301
2015 Okamura T, Antoun G, Keir ST, Friedman H, Bigner DD, Ali-Osman F. Phosphorylation of GSTP1 by EGFR Promotes Formation of the Inhibitory GSTP1-JNK Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. The Journal of Biological Chemistry. PMID 26429914 DOI: 10.1074/Jbc.M115.656140  0.38
2015 Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Bigner DD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121  0.498
2015 Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374  0.422
2015 Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, ... ... Bigner DD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/Nature14320  0.522
2015 Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. Journal of Neurochemistry. 133: 730-8. PMID 25598002 DOI: 10.1111/Jnc.13032  0.539
2015 Vlahovic G, Archer GE, Lally-Goss D, Reap E, Desjardins A, Peters KB, Randazzo D, Healy P, Herndon JE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 33: e13030-e13030. DOI: 10.1200/Jco.2016.34.15_Suppl.E13518  0.32
2015 Brown MC, Holl E, Boczkowski D, Walton R, Bigner DD, Gromeier M, Nair SK. Oncolytic poliovirus directs tumor antigen presentation and T cell activation in vitro Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P332  0.39
2015 Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Peckham JL, Cho Y, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, et al. Abstract A08: IGF1R as a key target in high risk, metastatic medulloblastoma Brain. 75. DOI: 10.1158/1538-7445.Brain15-A08  0.378
2015 Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Kwatra MM, Friedman HS, Bigner DD. Abstract 2435A: Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-2435A  0.384
2015 Dombrowski S, Abou-Antoun T, Mack S, Li X, Houghton P, Bigner D, Rich J, Recinos V. HG-06 * INHIBITION OF EPIGENETIC REGULATION AS A THERAPY FOR PEDIATRIC HIGH GRADE GLIOMA Neuro-Oncology. 17: iii11-iii11. DOI: 10.1093/Neuonc/Nov061.43  0.364
2014 Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang H, Wang XF. miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. The Journal of Clinical Investigation. 124: 4489-502. PMID 25202981 DOI: 10.1172/Jci75284  0.483
2014 Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Bigner DD, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093  0.489
2014 Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, Desjardins A, Sampson JH, Friedman HS, Friedman AH, Tyler DS, Bigner DD, Gromeier M. Oncolytic polio virotherapy of cancer. Cancer. 120: 3277-86. PMID 24939611 DOI: 10.1002/Cncr.28862  0.331
2014 Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, ... ... Bigner DD, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics. 46: 726-30. PMID 24880341 DOI: 10.1038/Ng.2995  0.549
2014 Babu R, Kranz PG, Agarwal V, McLendon RE, Thomas S, Friedman AH, Bigner DD, Adamson C. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. Journal of Neuro-Oncology. 119: 177-85. PMID 24838419 DOI: 10.1007/S11060-014-1471-9  0.575
2014 Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Plos One. 9: e94281. PMID 24722266 DOI: 10.1371/Journal.Pone.0094281  0.605
2014 Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, ... ... Bigner DD, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048 DOI: 10.18632/Oncotarget.1765  0.535
2014 Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581 DOI: 10.18632/Oncotarget.1505  0.525
2014 Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, Sanchez-Perez L, Bigner DD, Sampson JH. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 21: 189-90. PMID 24054399 DOI: 10.1016/J.Jocn.2013.03.012  0.388
2014 López GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathology and Applied Neurobiology. 40: 217-20. PMID 23659599 DOI: 10.1111/Nan.12060  0.531
2014 Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, Leon GD, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. D-270MG FLuc/GFP xenograft is highly invasive in NSG mice. Plos One. DOI: 10.1371/Journal.Pone.0094281.G001  0.458
2014 Vlahovic G, Archer GE, Lally-Goss D, Norman S, Desjardins A, Peters KB, Ranjan T, Watts J, Healy P, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 32: 3069-3069. DOI: 10.1200/Jco.2014.32.15_Suppl.3069  0.346
2014 Guo C, Chen LH, Huang Y, Chang C, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. Abstract LB-82: MLL2 maintains neoplastic cell growth and global histone H3 lysine 4 monomethylation Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-82  0.495
2014 Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Killela PJ, Yan H, Kwatra MM, Friedman HS, Bigner DD. Abstract 838: Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes Cancer Research. 74: 838-838. DOI: 10.1158/1538-7445.Am2014-838  0.369
2014 Pirozzi CJ, Wang CY, Carpenter AB, Zhu H, Greer PK, McLendon RE, Bigner DD, He Y, Yan H. Abstract 63: Driving brain tumorigenesis: Generation of a mutant IDH1 mouse model of progressive glioma Cancer Research. 74: 63-63. DOI: 10.1158/1538-7445.Am2014-63  0.575
2014 Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner D, Sampson J, Mitchell D. IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.8  0.428
2014 Vlahovic G, Archer G, Lally-Goss D, Reap E, Batich K, Desjardins A, Peters K, Ranjan T, Healy P, Herndon J, Friedman A, Friedman H, Bigner D, Sampson J. IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.32  0.329
2014 Keir S, Roskoski M, Gasinski D, Friedman H, Bigner D. ET-28 * COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB Neuro-Oncology. 16: v85-v85. DOI: 10.1093/Neuonc/Nou255.28  0.401
2014 Desjardins A, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Lipp E, Friedman A, Friedman H, Bigner D, Gromeier M. AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.21  0.336
2014 Kuan C, Pastan IH, Bigner DD. NEXT-GENERATION RECOMBINANT IMMUNOTOXINS FOR GLIOBLASTOMAS AND MELANOMAS TREATMENT Neuro-Oncology. 16: iii43-iii43. DOI: 10.1093/Neuonc/Nou209.6  0.408
2014 Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Friedman AH, Friedman HS, Bigner DD, Gromeier M. ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN RECURRENT GLIOBLASTOMA (GBM): FIRST PHASE I CLINICAL TRIAL EVALUATING THE INTRATUMORAL ADMINISTRATION Neuro-Oncology. 16: iii43-iii43. DOI: 10.1093/Neuonc/Nou209.5  0.345
2014 Gromeier M, Dobrikova E, Dobrikov M, Brown M, Bryant J, Threatt S, Boulton S, Carter K, Herndon J, Desjardins A, Friedman H, Sampson J, Friedman A, Bigner D. ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA Neuro-Oncology. 16: iii41-iii41. DOI: 10.1093/Neuonc/Nou208.69  0.383
2014 Archer GE, Reap E, Norberg P, Cui X, Schmittling R, Herndon J, Chandramohan V, Riccione K, Kuan C, Yan H, Bigner DD, Sampson JH. IDH1 MUTATIONS AS A IMMUNOTHERAPEUTIC TARGET FOR BRAIN TUMORS Neuro-Oncology. 16: iii40-iii40. DOI: 10.1093/Neuonc/Nou208.65  0.405
2014 Kwatra MM, Brown KE, Chagoya G, Keir ST, Bigner DD, Sampson JH. PATIENT-DERIVED XENOGRAFTS MIRROR THE PROTEOMIC PROFILE OF HUMAN GLIOBLASTOMA: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT Neuro-Oncology. 16: iii38-iii38. DOI: 10.1093/Neuonc/Nou208.57  0.406
2014 Keir ST, Roskoski MA, Gasinski D, Kwatra MK, Friedman HS, Bigner DD. IDENTIFICATION AND PRELIMINARY TREATMENT DATA OF XENOGRAFTS REPRESENTING TCGA-DEFINED SUBTYPES Neuro-Oncology. 16: iii35-iii35. DOI: 10.1093/Neuonc/Nou208.45  0.391
2013 Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs of the Future. 38: 147-155. PMID 25663738 DOI: 10.1358/Dof.2013.038.03.1933992  0.374
2013 Choi BD, Gedeon PC, Herndon JE, Archer GE, Reap EA, Sanchez-Perez L, Mitchell DA, Bigner DD, Sampson JH. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunology Research. 1: 163. PMID 24570975 DOI: 10.1158/2326-6066.Cir-13-0049  0.391
2013 Chandramohan V, Bigner DD. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunology. 2: e26852. PMID 24498557 DOI: 10.4161/Onci.26852  0.303
2013 Choi BD, Gedeon PC, Sanchez-Perez L, Bigner DD, Sampson JH. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology. 2: e26757. PMID 24475376 DOI: 10.4161/Onci.26757  0.34
2013 Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 4: 2144-53. PMID 24240169 DOI: 10.18632/Oncotarget.1555  0.517
2013 Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, ... ... Bigner DD, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica. 126: 917-29. PMID 24174164 DOI: 10.1007/S00401-013-1198-2  0.525
2013 Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, McLendon R, Bigner D, Fouladi M, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet. Oncology. 14: 1200-7. PMID 24140199 DOI: 10.1016/S1470-2045(13)70449-2  0.494
2013 Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Bigner DD, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/J.Cell.2013.09.034  0.348
2013 Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Journal of Neurosurgery. 119: 1415-23. PMID 24093630 DOI: 10.3171/2013.7.Jns1323  0.354
2013 Epple LM, Dodd RD, Merz AL, Dechkovskaia AM, Herring M, Winston BA, Lencioni AM, Russell RL, Madsen H, Nega M, Dusto NL, White J, Bigner DD, Nicchitta CV, Serkova NJ, et al. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. Plos One. 8: e73267. PMID 24039668 DOI: 10.1371/Journal.Pone.0073267  0.402
2013 Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology. 6: 375-86. PMID 23927666 DOI: 10.1586/17512433.2013.811806  0.391
2013 Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, MÃ¥nsson JE, Pastan IH, Bigner DD. Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. Mabs. 5: 748-62. PMID 23924792 DOI: 10.4161/Mabs.25860  0.363
2013 Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, ... ... Bigner DD, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genetics. 45: 1141-9. PMID 23917401 DOI: 10.1038/Ng.2734  0.518
2013 Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4717-27. PMID 23857604 DOI: 10.1158/1078-0432.Ccr-12-3891  0.552
2013 Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology (London, England). 9: 977-90. PMID 23837761 DOI: 10.2217/Fon.13.47  0.435
2013 Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods. 395: 14-20. PMID 23806556 DOI: 10.1016/J.Jim.2013.06.003  0.344
2013 Choi BD, Pastan I, Bigner DD, Sampson JH. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology. 2: e23639. PMID 23734318 DOI: 10.4161/Onci.23639  0.423
2013 Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, ... ... Bigner D, et al. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 4: 572-83. PMID 23592488 DOI: 10.18632/Oncotarget.964  0.498
2013 Sanchez-Perez L, Choi BD, Reap EA, Sayour EJ, Norberg P, Schmittling RJ, Archer GE, Herndon JE, Mitchell DA, Heimberger AB, Bigner DD, Sampson JH. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology, Immunotherapy : Cii. 62: 983-7. PMID 23591978 DOI: 10.1007/S00262-013-1405-Y  0.329
2013 Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. Journal of Neurosurgery. 118: 1176-80. PMID 23581583 DOI: 10.3171/2013.3.Jns122282  0.354
2013 Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... Bigner DD, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18  0.587
2013 Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE, Bigner DD, Mitchell DA, Sampson JH. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. Plos One. 8: e59082. PMID 23527092 DOI: 10.1371/Journal.Pone.0059082  0.377
2013 Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, Keir ST, Yan H, Bigner DD, Simpkins JW, Yang SH. Reversing the Warburg effect as a treatment for glioblastoma. The Journal of Biological Chemistry. 288: 9153-64. PMID 23408428 DOI: 10.1074/Jbc.M112.440354  0.356
2013 Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America. 110: 270-5. PMID 23248284 DOI: 10.1073/Pnas.1219817110  0.438
2013 Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 73: 496-501. PMID 23204232 DOI: 10.1158/0008-5472.Can-12-2852  0.514
2013 Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. International Journal of Cancer. Journal International Du Cancer. 132: 2339-48. PMID 23115013 DOI: 10.1002/Ijc.27919  0.422
2013 Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. Journal of Neuro-Oncology. 111: 97-102. PMID 23086436 DOI: 10.1007/S11060-012-0995-0  0.331
2013 Sampson JH, Desjardins A, Peters KB, Ranjan T, Vlahovic G, Lally-Goss D, Threatt S, Herndon J, Friedman AH, Friedman H, Bigner D, Gromeier M. 107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma Neurosurgery. 60: 155. DOI: 10.1200/Jco.2013.31.15_Suppl.2094  0.398
2013 Bao X, Chandramohan V, Keir ST, Pegram CN, McLendon RE, Kuan C, Pastan IH, Bigner DD. Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P126  0.532
2013 Keir ST, Roskoski MA, Kragh M, Pederson MW, Jacobsen HJ, Horak ID, Friedman HS, Bigner DD. Abstract 4322: Efficacy of Sym004, a novel anti-EGFR antibody mixture, against EGFRvIII positive glioblastoma xenografts. Cancer Research. 73: 4322-4322. DOI: 10.1158/1538-7445.Am2013-4322  0.418
2013 Keir ST, Roskoski MA, Wagner S, Tiedt R, Bigner DD, Friedman HS. Abstract 2079: Antitumoral activity of INC280 against adult glioblastoma brain tumors xenografts. Cancer Research. 73: 2079-2079. DOI: 10.1158/1538-7445.Am2013-2079  0.41
2012 Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/Nm.2994  0.345
2012 Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X, Cho YW, Chi JT, Grant GA, McLendon RE, Yan H, Ge K, Papadopoulos N, Bigner DD, He Y. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 109: 17603-8. PMID 23045699 DOI: 10.1073/Pnas.1208807109  0.482
2012 Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer. 107: 1481-7. PMID 23037712 DOI: 10.1038/Bjc.2012.415  0.312
2012 Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Research. 22: 2339-55. PMID 22899282 DOI: 10.1101/Gr.132738.111  0.312
2012 Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He Y, Yan H. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget. 3: 774-82. PMID 22885298 DOI: 10.18632/Oncotarget.577  0.37
2012 Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM. Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Journal of Neuro-Oncology. 110: 163-77. PMID 22875710 DOI: 10.1007/S11060-012-0958-5  0.41
2012 Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, ... ... Bigner DD, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205 DOI: 10.18632/Oncotarget.588  0.647
2012 Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, ... ... Bigner DD, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 488: 49-56. PMID 22832581 DOI: 10.1038/Nature11327  0.507
2012 Wortham M, Jin G, Sun JL, Bigner DD, He Y, Yan H. Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells. Plos One. 7: e36211. PMID 22558385 DOI: 10.1371/Journal.Pone.0036211  0.361
2012 Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clinical & Developmental Immunology. 2012: 480429. PMID 22400035 DOI: 10.1155/2012/480429  0.438
2012 Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. Plos One. 7: e31046. PMID 22383993 DOI: 10.1371/Journal.Pone.0031046  0.509
2012 Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, Duncan C, McLendon R, Bigner D, Gregory S, Adamson DC. Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Molecular Cancer Research : McR. 10: 208-17. PMID 22241217 DOI: 10.1158/1541-7786.Mcr-10-0109  0.583
2012 Marshall D, Mitchell DA, Graner MW, Bigner DD. Immunotherapy of brain tumors. Handbook of Clinical Neurology. 104: 309-30. PMID 22230450 DOI: 10.1016/B978-0-444-52138-5.00020-7  0.375
2012 Jones S, Li M, Williams Parsons D, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D, Hruban RH, Eshleman JR, Iacobuzio-Donahue CA, Goggins M, Maitra A, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types Human Mutation. 33: 100-103. PMID 22009941 DOI: 10.1002/Humu.21633  0.357
2012 Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology. 39: 23-34. PMID 21958852 DOI: 10.1016/J.Nucmedbio.2011.06.005  0.572
2012 Wortham M, Jin G, Sun JL, Bigner DD, Yan H. Abstract 3352: The medulloblastoma oncogene Otx2 enhances migration and permits ectopic proliferation of neuronal progenitor cells of the cerebellum and brainstem Cancer Research. 72: 3352-3352. DOI: 10.1158/1538-7445.Am2012-3352  0.348
2012 Hedegaard CJ, Pegram CN, Bigner DD, Poulsen HS. Abstract 2732: Internalization of the dual-specific immunotoxin D2C7-(scdsFv)-PE38KDEL in malignant glioma cell lines Cancer Research. 72: 2732-2732. DOI: 10.1158/1538-7445.Am2012-2732  0.361
2012 Pollack IF, Jakacki RI, Butterfield L, Okada H, Chiba Y, Hashimoto N, Kagawa N, Kinoshita M, Kijima N, Hirayama R, Oji Y, Tsuboi A, Oka Y, Sugiyama H, Yoshimine T, ... ... Bigner D, ... ... Bigner DD, ... ... Bigner D, et al. CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES Neuro-Oncology. 14: vi43-vi49. DOI: 10.1093/Neuonc/Nos224  0.451
2012 Fujita M, Zhang R, Nakata S, Kuzushima K, Wainwright DA, Balyasnikova IV, Auffinger B, Ahmed AU, Han Y, Lesniak MS, Knight A, Arnouk H, Gillespie GY, Britt W, Su Y, ... ... Bigner DD, ... ... Bigner DD, ... ... Bigner DD, ... ... Bigner DD, et al. LAB-IMMUNOLOGY RESEARCH Neuro-Oncology. 14: vi38-vi42. DOI: 10.1093/Neuonc/Nos223  0.416
2011 Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD, Pastan I, Sampson JH. Imaging of convection enhanced delivery of toxins in humans. Toxins. 3: 201-6. PMID 22069706 DOI: 10.3390/Toxins3030201  0.352
2011 Mehta AI, Kanaly CW, Friedman AH, Bigner DD, Sampson JH. Monitoring radiographic brain tumor progression. Toxins. 3: 191-200. PMID 22069705 DOI: 10.3390/Toxins3030191  0.399
2011 Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (New York, N.Y.). 333: 1453-5. PMID 21817013 DOI: 10.1126/Science.1210557  0.55
2011 Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 118: 3003-12. PMID 21768296 DOI: 10.1182/Blood-2011-02-334565  0.509
2011 Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, ... Bigner DD, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science (New York, N.Y.). 333: 425. PMID 21719641 DOI: 10.1126/Science.1207313  0.557
2011 Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4119-24. PMID 21531816 DOI: 10.1158/1078-0432.Ccr-11-0120  0.303
2011 Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146 DOI: 10.6004/Jnccn.2011.0038  0.561
2011 Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion On Biological Therapy. 11: 843-53. PMID 21449821 DOI: 10.1517/14712598.2011.572874  0.36
2011 Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, Reardon DA, Friedman AH, Bigner DD, Sampson JH. A novel method for volumetric MRI response assessment of enhancing brain tumors. Plos One. 6: e16031. PMID 21298088 DOI: 10.1371/Journal.Pone.0016031  0.381
2011 Keir ST, Dewhirst MW, Kirkpatrick JP, Bigner DD, Batinic-Haberle I. Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. Anti-Cancer Agents in Medicinal Chemistry. 11: 202-12. PMID 21291403 DOI: 10.2174/187152011795255957  0.382
2011 Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences of the United States of America. 108: 3270-5. PMID 21289278 DOI: 10.1073/Pnas.1019393108  0.336
2011 Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, ... ... Bigner DD, et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, N.Y.). 331: 435-9. PMID 21163964 DOI: 10.1126/Science.1198056  0.635
2011 Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, ... ... Bigner DD, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157  0.593
2011 Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE, Pastan I, Bigner DD. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. International Journal of Cancer. Journal International Du Cancer. 129: 111-21. PMID 20824708 DOI: 10.1002/Ijc.25645  0.344
2011 Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/S11060-010-0217-6  0.546
2011 Mehta AI, Persson O, Herndon JE, Archer GE, McLendon R, Heimberger AB, Mitchell DA, Bigner DD, Sampson JH. Reply to M.S. Lesniak Journal of Clinical Oncology. 29: 3105-3106. DOI: 10.1200/Jco.2011.35.0256  0.416
2011 Yan H, Reitman ZJ, Jin G, Spasojevic I, He Y, Bigner DD, Karoly ED, Yang J, Kinzler KW, Vogelstein B. Abstract LB-257: Profiling the effects of IDH1 and IDH2 mutants on the glioma cell metabolome Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-257  0.324
2011 Liu I, Keir S, Rasheed BA, Bigner D. Abstract 4417: Characterization of xenograft-derived EGFRvIII-positive GBM cell cultures reveals functional interactions between EGFRvIII, wild-type EGFR, and p53 Cancer Research. 71: 4417-4417. DOI: 10.1158/1538-7445.Am2011-4417  0.344
2011 Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Bigner DD, ... ... Bigner D, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158  0.312
2011 Batinic-Haberle I, Keir ST, Rajic Z, Tovmasyan A, Bigner DD. Lipophilic Mn Porphyrins in the Treatment of Brain Tumors Free Radical Biology and Medicine. 51: S119-S120. DOI: 10.1016/J.Freeradbiomed.2011.10.309  0.36
2010 Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. Journal of Biomedical Research. 24: 424-35. PMID 23554659 DOI: 10.1016/S1674-8301(10)60057-7  0.313
2010 Adamson DC, Rasheed BA, McLendon RE, Bigner DD. Central nervous system. Cancer Biomarkers : Section a of Disease Markers. 9: 193-210. PMID 22112477 DOI: 10.3233/Cbm-2011-0177  0.588
2010 Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 1: 265-77. PMID 21113414 DOI: 10.18632/Oncotarget.137  0.526
2010 Kuan CT, Chang J, Mansson JE, Li J, Pegram C, Fredman P, McLendon RE, Bigner DD. Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. Bmc Developmental Biology. 10: 114. PMID 21087515 DOI: 10.1186/1471-213X-10-114  0.48
2010 Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, ... Bigner DD, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/Jco.2010.28.6963  0.529
2010 Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nuclear Medicine and Biology. 37: 785-94. PMID 20870153 DOI: 10.1016/J.Nucmedbio.2010.03.010  0.371
2010 Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology. 37: 741-50. PMID 20870149 DOI: 10.1016/J.Nucmedbio.2010.04.020  0.368
2010 Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. Bmc Cancer. 10: 468. PMID 20809959 DOI: 10.1186/1471-2407-10-468  0.555
2010 Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 29: 5135-45. PMID 20622897 DOI: 10.1038/Onc.2009.279  0.376
2010 Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/J.Bbrc.2010.06.125  0.532
2010 Jin G, Cook S, Cui B, Chen WC, Keir ST, Killela P, Di C, Payne CA, Gregory SG, McLendon R, Bigner DD, Yan H. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology. 12: 956-66. PMID 20472715 DOI: 10.1093/Neuonc/Noq045  0.556
2010 Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Research. 70: 181-91. PMID 20028867 DOI: 10.1158/0008-5472.Can-09-2331  0.594
2010 Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, MÃ¥nsson JE, Bigner DD. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochemical and Biophysical Research Communications. 391: 750-5. PMID 19944071 DOI: 10.1016/J.Bbrc.2009.11.132  0.514
2010 Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. International Journal of Cancer. Journal International Du Cancer. 127: 598-611. PMID 19937796 DOI: 10.1002/Ijc.25062  0.538
2010 Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer. Journal International Du Cancer. 127: 245-6. PMID 19877121 DOI: 10.1002/Ijc.25017  0.417
2010 Sampson JH, Archer GE, Schmittling R, Herndon JE, Coan AD, Reardon DA, Verdenburgh J, Desjardins A, Dechkovskaia A, McGehee-Norman S, Lally-Goss D, Perry BA, Friedman A, Friedman HS, Bigner DD, et al. Abstract 5611: Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses Cancer Research. 70: 5611-5611. DOI: 10.1158/1538-7445.Am10-5611  0.366
2010 Cai M, Choi B, Bigner DD, Sampson JH, Kuan C. Abstract 4409: A bispecific T-cell engager effectively eradicates EGFRvIII-expressing glioblastoma multiforme Cancer Research. 70: 4409-4409. DOI: 10.1158/1538-7445.Am10-4409  0.45
2010 Wortham M, Adamson DC, Shi Q, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. Abstract 233: OTX2 copy number gain is a driver event in Shh-independent medulloblastomas Cancer Research. 70: 233-233. DOI: 10.1158/1538-7445.Am10-233  0.582
2009 Adamson DC, Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, Duncan C, McLendon R, Bigner D. Genome Mapping of Glioblastoma Identifies a Novel Epigenetically-Silenced, Migration-Related Gene, Adherens Junctional Associated Protein, Whose Restoration of Expression by Demethylating Agents Can Inhibit Cell Migration: 972. Neurosurgery. 65: 424. PMID 28173148 DOI: 10.1227/01.Neu.0000358743.40035.E3  0.479
2009 Heimberger AB, Archer GE, Mitchell DA, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Sampson JH. Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2021. PMID 27964605 DOI: 10.1200/Jco.2009.27.15_Suppl.2021  0.362
2009 Herndon J, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13016. PMID 27962830 DOI: 10.1200/Jco.2009.27.15_Suppl.E13016  0.324
2009 Peters K, Desjardins A, Reardon DA, Perry S, Herndon JE, Bailey L, Friedman AH, Friedman HS, Bigner DD, Vredenburgh JJ. Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13025. PMID 27962792 DOI: 10.1200/Jco.2009.27.15_Suppl.E13025  0.365
2009 Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (2005). 28: 389-403. PMID 20025498 DOI: 10.1089/Hyb.2009.0049  0.506
2009 Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Research. 69: 9157-9. PMID 19996293 DOI: 10.1158/0008-5472.Can-09-2650  0.313
2009 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/Sj.Bjc.6605412  0.526
2009 Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Research. 69: 9105-11. PMID 19920201 DOI: 10.1158/0008-5472.Can-09-2775  0.585
2009 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8: 2773-9. PMID 19825799 DOI: 10.1158/1535-7163.Mct-09-0124  0.389
2009 Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications. 390: 547-51. PMID 19818334 DOI: 10.1016/J.Bbrc.2009.10.001  0.526
2009 Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clinical Medicine. Oncology. 3: 39-52. PMID 19777070 DOI: 10.4137/Cmo.S1008  0.39
2009 Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology (Zurich, Switzerland). 19: 713-23. PMID 19744042 DOI: 10.1111/J.1750-3639.2009.00318.X  0.536
2009 Graner MW, Raynes DA, Bigner DD, Guerriero V. Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Science. 100: 1870-9. PMID 19659607 DOI: 10.1111/J.1349-7006.2009.01269.X  0.365
2009 Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 36: 659-69. PMID 19647172 DOI: 10.1016/J.Nucmedbio.2009.04.003  0.507
2009 Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemotherapy and Pharmacology. 64: 1053-8. PMID 19597728 DOI: 10.1007/S00280-009-1063-0  0.326
2009 Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. Sample type bias in the analysis of cancer genomes. Cancer Research. 69: 5630-3. PMID 19567670 DOI: 10.1158/0008-5472.Can-09-1055  0.324
2009 Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion On Investigational Drugs. 18: 1061-83. PMID 19555299 DOI: 10.1517/13543780903052764  0.39
2009 Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 115: 3501-11. PMID 19514083 DOI: 10.1002/Cncr.24398  0.32
2009 Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, Adamson DC. Glioblastoma multiforme: a review of therapeutic targets. Expert Opinion On Therapeutic Targets. 13: 701-18. PMID 19409033 DOI: 10.1517/14728220902942348  0.42
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007  0.476
2009 Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. The Journal of Biological Chemistry. 284: 16979-89. PMID 19254954 DOI: 10.1074/Jbc.M808153200  0.344
2009 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, ... ... Bigner DD, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/Nejmoa0808710  0.56
2009 Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/Jco.2008.18.8417  0.512
2009 Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.Ccr-08-2130  0.525
2009 Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Proteomic and immunologic analyses of brain tumor exosomes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 1541-57. PMID 19109410 DOI: 10.1096/Fj.08-122184  0.413
2009 Liu Y, Kuan CT, Mi J, Zhang X, Clary BM, Bigner DD, Sullenger BA. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biological Chemistry. 390: 137-44. PMID 19040357 DOI: 10.1515/Bc.2009.022  0.333
2008 Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2011. PMID 27948414 DOI: 10.1200/Jco.2008.26.15_Suppl.2011  0.406
2008 Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Research. 68: 10300-6. PMID 19074898 DOI: 10.1158/0008-5472.Can-08-3272  0.378
2008 Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.Ccr-08-0260  0.36
2008 Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 339: 74-81. PMID 18775433 DOI: 10.1016/J.Jim.2008.08.004  0.354
2008 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, ... ... Bigner DD, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.). 321: 1807-12. PMID 18772396 DOI: 10.1126/Science.1164382  0.554
2008 Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4859-68. PMID 18676759 DOI: 10.1158/1078-0432.Ccr-07-4807  0.499
2008 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology. 20: 267-75. PMID 18539480 DOI: 10.1016/J.Smim.2008.04.001  0.45
2008 Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Review of Anticancer Therapy. 8: 717-32. PMID 18471045 DOI: 10.1586/14737140.8.5.717  0.385
2008 Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, ... ... Bigner DD, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012  0.565
2008 Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, ... ... Bigner DD, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 10: 182-9. PMID 18287339 DOI: 10.1215/15228517-2007-053  0.532
2008 Mott RT, Turner KC, Bigner DD, McLendon RE. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. Journal of Neurosurgery. 108: 330-5. PMID 18240930 DOI: 10.3171/Jns/2008/108/2/0330  0.57
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.Ccr-07-1966  0.304
2008 Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-Oncology. 10: 98-103. PMID 18079360 DOI: 10.1215/15228517-2007-046  0.317
2008 Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 30-8. PMID 18077533 DOI: 10.2967/Jnumed.107.046938  0.584
2008 Ochiai H, Archer GE, Herndon JE, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunology, Immunotherapy : Cii. 57: 115-21. PMID 17634939 DOI: 10.1007/S00262-007-0363-7  0.409
2008 Mitchell D, Archer GE, Bigner DD, Friedman HS, Lally-Goss D, Herndon JE, McGehee S, McLendon R, Reardon DA, Sampson JH. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM Journal of Clinical Oncology. 26: 2042-2042. DOI: 10.1200/Jco.2008.26.15_Suppl.2042  0.565
2007 Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/Jco.2007.12.2440  0.345
2007 Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11214-27. PMID 17942716 DOI: 10.1523/Jneurosci.3588-07.2007  0.358
2007 Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nuclear Medicine and Biology. 34: 779-85. PMID 17921029 DOI: 10.1016/J.Nucmedbio.2007.03.007  0.319
2007 Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics. 6: 2449-57. PMID 17766837 DOI: 10.1158/1535-7163.Mct-07-0155  0.366
2007 Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro-Oncology. 9: 240-4. PMID 17522334 DOI: 10.1215/15228517-2007-011  0.371
2007 McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 34: 405-13. PMID 17499730 DOI: 10.1016/J.Nucmedbio.2007.01.009  0.549
2007 Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Review of Anticancer Therapy. 7: 675-87. PMID 17492931 DOI: 10.1586/14737140.7.5.675  0.413
2007 Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1253-9. PMID 17317837 DOI: 10.1158/1078-0432.Ccr-06-2309  0.34
2007 Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nuclear Medicine and Biology. 34: 173-83. PMID 17307125 DOI: 10.1016/J.Nucmedbio.2006.11.003  0.311
2007 Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Molecular Carcinogenesis. 46: 488-96. PMID 17219439 DOI: 10.1002/Mc.20297  0.328
2007 Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 26: 4084-94. PMID 17213807 DOI: 10.1038/Sj.Onc.1210181  0.344
2007 Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro-Oncology. 9: 70-4. PMID 17108065 DOI: 10.1215/15228517-2006-022  0.31
2007 Sampson JH, Aldape KD, Gilbert MR, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell D, Bigner DD, Reardon DA, Heimberger AB. Temozolomide as a vaccine adjuvant in GBM Journal of Clinical Oncology. 25: 2020-2020. DOI: 10.1200/Jco.2007.25.18_Suppl.2020  0.326
2006 Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444: 756-60. PMID 17051156 DOI: 10.1038/Nature05236  0.514
2006 Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 5: 2531-9. PMID 17041097 DOI: 10.1158/1535-7163.Mct-06-0106  0.511
2006 Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5064-73. PMID 16951222 DOI: 10.1158/1078-0432.Ccr-06-0913  0.376
2006 Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.Can-06-0284  0.58
2006 Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research. 66: 7843-8. PMID 16912155 DOI: 10.1158/0008-5472.Can-06-1010  0.585
2006 Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4294-305. PMID 16857805 DOI: 10.1158/1078-0432.Ccr-06-0053  0.311
2006 Graner MW, Bigner DD. Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. Expert Review of Anticancer Therapy. 6: 679-95. PMID 16759160 DOI: 10.1586/14737140.6.5.679  0.329
2006 Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, ... ... Bigner DD, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299  0.497
2006 Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1970-82. PMID 16609006 DOI: 10.1158/1078-0432.Ccr-05-2797  0.413
2006 Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research. 66: 3294-302. PMID 16540683 DOI: 10.1158/0008-5472.Can-05-3773  0.304
2006 Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1253-65. PMID 16525180 DOI: 10.1200/Jco.2005.04.5302  0.385
2006 Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, ... ... Bigner DD, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.Ccr-05-2215  0.542
2006 Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nuclear Medicine and Biology. 33: 101-10. PMID 16459265 DOI: 10.1016/J.Nucmedbio.2005.08.004  0.362
2006 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, ... ... Bigner DD, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 115-22. PMID 16382120 DOI: 10.1200/Jco.2005.03.4082  0.569
2006 Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM Journal of Clinical Oncology. 24: 2529-2529. DOI: 10.1200/Jco.2006.24.18_Suppl.2529  0.402
2006 Rich JN, Shi Q, Hjelmeland AB, Keir ST, Wickman S, Wu G, Jackson D, Ohmori O, Bigner DD, Friedman HS. A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth Journal of Clinical Oncology. 24: 11505-11505. DOI: 10.1200/Jco.2006.24.18_Suppl.11505  0.367
2005 Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8145-57. PMID 16299247 DOI: 10.1158/1078-0432.Ccr-05-0319  0.573
2005 Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. The New England Journal of Medicine. 353: 1997-9. PMID 16282174 DOI: 10.1056/Nejmp058186  0.352
2005 Rizzieri DA, Wadleigh M, Wikstrand CJ, Mann KP, Sen F, Peterson BL, Niedzwiecki D, Proia AD, Bigner DD. Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. Leukemia & Lymphoma. 46: 1455-62. PMID 16194891 DOI: 10.1080/10428190500158060  0.565
2005 Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, ... ... Bigner DD, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/Jco.2005.06.502  0.503
2005 Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Molecular Cancer Therapeutics. 4: 1364-8. PMID 16170028 DOI: 10.1158/1535-7163.Mct-05-0128  0.347
2005 McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 104: 1693-9. PMID 16116609 DOI: 10.1002/cncr.21362  0.48
2005 Graner MW, Bigner DD. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro-Oncology. 7: 260-78. PMID 16053701 DOI: 10.1215/S1152851704001188  0.387
2005 Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2645-68. PMID 15970525 DOI: 10.2741/1727  0.36
2005 Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, ... Bigner DD, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1042-51. PMID 15937318  0.506
2005 Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research. 65: 4051-8. PMID 15899794 DOI: 10.1158/0008-5472.Can-04-3936  0.532
2005 Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research. 65: 919-24. PMID 15705891  0.466
2005 Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589  0.568
2005 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358  0.489
2005 Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer (Amsterdam, Netherlands). 47: 17-29. PMID 15603851 DOI: 10.1016/J.Lungcan.2004.05.016  0.321
2005 Friedman HS, Quinn J, Rich J, Vredenburgh J, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Reardon D. Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results Journal of Clinical Oncology. 23: 1515-1515. DOI: 10.1200/Jco.2005.23.16_Suppl.1515  0.359
2004 Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, Vredenburgh JJ, Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1569. PMID 28015735 DOI: 10.1200/Jco.2004.22.14_Suppl.1569  0.362
2004 Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). Journal of Immunology (Baltimore, Md. : 1950). 173: 6472-80. PMID 15528389 DOI: 10.4049/Jimmunol.173.10.6472  0.33
2004 Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. The Journal of Biological Chemistry. 279: 52200-9. PMID 15469933 DOI: 10.1074/Jbc.M409630200  0.377
2004 Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nuclear Medicine and Biology. 31: 909-19. PMID 15464393 DOI: 10.1016/J.Nucmedbio.2004.04.007  0.35
2004 Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opinion On Biological Therapy. 4: 1453-71. PMID 15335313 DOI: 10.1517/14712598.4.9.1453  0.33
2004 Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 64: 5048-50. PMID 15289301 DOI: 10.1158/0008-5472.Can-04-1170  0.533
2004 Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-Oncology. 6: 208-17. PMID 15279713 DOI: 10.1215/S1152851703000577  0.37
2004 Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics : Jmd. 6: 166-79. PMID 15269292 DOI: 10.1016/S1525-1578(10)60507-7  0.52
2004 Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nature Reviews. Drug Discovery. 3: 430-46. PMID 15136790 DOI: 10.1038/Nrd1380  0.332
2004 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology. 6: 145-53. PMID 15134629 DOI: 10.1215/S1152851703000498  0.304
2004 Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3216-24. PMID 15131063 DOI: 10.1158/1078-0432.Ccr-03-0521  0.347
2004 Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B, Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C, Gasparetto C, ... ... Bigner DD, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 104: 642-8. PMID 15100153 DOI: 10.1182/Blood-2003-12-4264  0.385
2004 Castillo MS, Davis FG, Surawicz T, Bruner JM, Bigner S, Coons S, Bigner DD. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiology. 23: 85-93. PMID 14739573 DOI: 10.1159/000073980  0.391
2004 Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, ... ... Bigner DD, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/Jco.2004.08.110  0.542
2003 Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5514-20. PMID 14654531  0.456
2003 Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809  0.576
2003 Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology. 64: 161-76. PMID 12952297 DOI: 10.1007/Bf02700031  0.38
2003 Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. Nuclear Medicine and Biology. 30: 351-9. PMID 12767391 DOI: 10.1016/S0969-8051(03)00005-2  0.312
2003 Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. The Journal of Biological Chemistry. 278: 15951-7. PMID 12590137 DOI: 10.1074/Jbc.M211498200  0.415
2003 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/Jco.2003.01.009  0.54
2002 Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3496-502. PMID 12429640  0.523
2002 Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of Radiation Oncology, Biology, Physics. 54: 1259-75. PMID 12419456 DOI: 10.1016/S0360-3016(02)03794-X  0.516
2002 Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 94: 2688-97. PMID 12173338 DOI: 10.1002/cncr.10544  0.484
2002 Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, ... ... Bigner DD, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/Jco.2002.09.084  0.541
2002 Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro-Oncology. 4: 75-85. PMID 11916498 DOI: 10.1093/Neuonc/4.2.75  0.481
2002 Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, ... ... Bigner DD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/Jco.20.5.1389  0.539
2002 Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunology, Immunotherapy : Cii. 50: 639-52. PMID 11862416 DOI: 10.1007/S00262-001-0243-5  0.39
2002 Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024  0.564
2002 Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nuclear Medicine and Biology. 29: 1-11. PMID 11786270 DOI: 10.1016/S0969-8051(01)00277-3  0.388
2001 Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 413-6. PMID 11761460 DOI: 10.1007/S002800100358  0.375
2001 Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 48: 250-4. PMID 11592348 DOI: 10.1007/S002800100347  0.332
2001 Foulon CF, Welsh PC, Bigner DD, Zalutsky MR. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nuclear Medicine and Biology. 28: 769-77. PMID 11578897 DOI: 10.1016/S0969-8051(01)00239-6  0.341
2001 Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 83-7. PMID 11488529 DOI: 10.1007/S002800000274  0.332
2001 Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocrine-Related Cancer. 8: 83-96. PMID 11397666 DOI: 10.1677/Erc.0.0080083  0.378
2001 Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Research. 61: 3556-60. PMID 11325817  0.497
2000 Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathology. 17: 71-8. PMID 11210174 DOI: 10.1007/Bf02482738  0.392
2000 Kuan CT, Wikstrand CJ, Archer G, Beers R, Pastan I, Zalutsky MR, Bigner DD. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer. Journal International Du Cancer. 88: 962-9. PMID 11093822 DOI: 10.1002/1097-0215(20001215)88:6<962::Aid-Ijc20>3.0.Co;2-U  0.359
2000 Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, ... ... Bigner DD, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3862-72. PMID 11078500 DOI: 10.1200/Jco.2000.18.22.3862  0.532
2000 Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4148-53. PMID 11051269  0.462
2000 Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, ... ... Bigner DD, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3522-8. PMID 11032594 DOI: 10.1200/jco.2000.18.20.3522  0.403
2000 Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Research. 10: 1393-402. PMID 10984457 DOI: 10.1101/Gr.138000  0.358
2000 Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF. Design of a novel small peptide targeted against a tumor-specific receptor. Biochemical and Biophysical Research Communications. 275: 631-6. PMID 10964715 DOI: 10.1006/Bbrc.2000.3347  0.347
2000 McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 48: 1103-10. PMID 10898803 DOI: 10.1177/002215540004800807  0.591
2000 Keir ST, Dolan ME, Pegg AE, Lawless A, Moschel RC, Bigner DD, Friedman HS. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemotherapy and Pharmacology. 45: 437-40. PMID 10854129 DOI: 10.1007/S002800051016  0.383
2000 Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 97: 7503-8. PMID 10852962 DOI: 10.1073/Pnas.130166597  0.453
2000 Aldosari N, Rasheed BK, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathologica. 99: 345-51. PMID 10787031 DOI: 10.1007/S004010051134  0.475
2000 Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemotherapy and Pharmacology. 45: 345-9. PMID 10755324 DOI: 10.1007/S002800050050  0.348
2000 Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation Oncology, Biology, Physics. 46: 947-58. PMID 10705017 DOI: 10.1016/S0360-3016(99)00500-3  0.541
2000 Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology. 103: 16-25. PMID 10674985 DOI: 10.1016/S0165-5728(99)00172-1  0.558
1999 Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Reviews. 18: 451-64. PMID 10855788 DOI: 10.1023/A:1006354102377  0.336
1999 Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology. 44: 233-41. PMID 10720203 DOI: 10.1023/A:1006304424346  0.454
1999 Foulon CF, Bigner DD, Zalutsky MR. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjugate Chemistry. 10: 867-76. PMID 10502355 DOI: 10.1021/Bc990040W  0.346
1999 Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 2646-52. PMID 10499644  0.541
1999 McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 45: 491-9. PMID 10487576 DOI: 10.1016/S0360-3016(99)00206-0  0.513
1999 Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. The American Journal of Pathology. 155: 375-86. PMID 10433931 DOI: 10.1016/S0002-9440(10)65134-6  0.541
1999 Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nuclear Medicine and Biology. 26: 405-11. PMID 10382844 DOI: 10.1016/S0969-8051(98)00120-6  0.309
1999 Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755 DOI: 10.1097/00006123-199909000-00095  0.529
1999 Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, ... Bigner DD, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1516-25. PMID 10334539 DOI: 10.1200/Jco.1999.17.5.1516  0.525
1999 Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Current Opinion in Oncology. 11: 162-7. PMID 10328589 DOI: 10.1097/00001622-199905000-00004  0.369
1998 Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, ... ... Bigner DD, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030 DOI: 10.1200/Jco.1998.16.12.3851  0.56
1998 Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277 DOI: 10.1200/Jco.1998.16.11.3570  0.539
1998 Ashley DM, Sampson JH, Archer GE, Hale LP, Bigner DD. Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. Journal of Neuroimmunology. 86: 46-52. PMID 9655471 DOI: 10.1016/S0165-5728(98)00017-4  0.35
1998 Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2202-12. PMID 9626222 DOI: 10.1200/Jco.1998.16.6.2202  0.57
1998 McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 78: 643-4. PMID 9605190  0.359
1998 s M, Rasheed B, McLendon RE, Wikstrand CJ, Bigner DD, Bigner SH. MOLECULAR AND IMMUNOHISTOLOGIC (IHC) STUDIES ON OLIGODENDROGLIAL (O) TUMORS Journal of Neuropathology and Experimental Neurology. 57: 473. DOI: 10.1097/00005072-199805000-00029  0.523
1997 Ashley DM, Batra SK, Bigner DD. Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. Journal of Neuro-Oncology. 35: 259-73. PMID 9440024 DOI: 10.1023/A:1005812417638  0.343
1997 Ashley DM, Bigner DD. Recent advances in the biology of central nervous system tumors. Current Opinion in Neurology. 10: 445-51. PMID 9425557 DOI: 10.1097/00019052-199712000-00002  0.401
1997 Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery. 41: 1365-72; discussion . PMID 9402588 DOI: 10.1097/00006123-199712000-00024  0.386
1997 Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nuclear Medicine and Biology. 24: 639-47. PMID 9352535 DOI: 10.1016/S0969-8051(97)00080-2  0.373
1997 Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research. 57: 4187-90. PMID 9331072  0.479
1997 Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. The Journal of Experimental Medicine. 186: 1177-82. PMID 9314567 DOI: 10.1084/Jem.186.7.1177  0.358
1997 Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Research. 57: 4130-40. PMID 9307304  0.504
1997 Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. Journal of Neuroimmunology. 78: 34-46. PMID 9307226 DOI: 10.1016/S0165-5728(97)00080-5  0.395
1997 Zalutsky MR, Stabin MG, Larsen RH, Bigner DD. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. Nuclear Medicine and Biology. 24: 255-61. PMID 9228660 DOI: 10.1016/S0969-8051(97)00060-7  0.317
1997 Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). The Biochemical Journal. 324: 855-61. PMID 9210410 DOI: 10.1042/Bj3240855  0.544
1997 Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39: 307-16. PMID 9025771 DOI: 10.1007/S002800050577  0.53
1997 Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 39: 187-91. PMID 8996518 DOI: 10.1007/S002800050558  0.392
1997 Matthews M, Friedman A, Wikstrand C, Bigner D, McLendon R. EXTRACELLULAR MATRIX ANTIGENS IN CAPILLARY HEMANGIOBLASTOMA Journal of Neuropathology and Experimental Neurology. 56: 612. DOI: 10.1097/00005072-199705000-00179  0.442
1997 Bean J, Archer G, Munley M, Ong E, Snyder S, Haroon Z, McLendon R, Marks L, Stratford M, Chaplin D, Brizel D, Bigner D, Dewhirst M. 2013 The impact of hypoxia and oxygenation modification on the radiation response of an intracranial rat glioma International Journal of Radiation Oncology*Biology*Physics. 39: 247. DOI: 10.1016/S0360-3016(97)80782-1  0.454
1996 Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, ... ... Bigner DD, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 2: 963-72. PMID 9816257  0.482
1996 Zalutsky MR, Archer GE, Garg PK, Batra SK, Bigner DD. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nuclear Medicine and Biology. 23: 449-58. PMID 8832699 DOI: 10.1016/0969-8051(96)00021-2  0.352
1996 Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 93: 10399-404. PMID 8816812 DOI: 10.1073/Pnas.93.19.10399  0.373
1996 Fredman P, Wikstrand CJ, MÃ¥nsson JE, Reifenberger G, Bigner SH, Rasheed A, Svennerholm L, Bigner DD. In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line. Glycoconjugate Journal. 13: 391-9. PMID 8781970 DOI: 10.1007/Bf00731472  0.352
1996 Zalutsky MR, Schuster JM, Garg PK, Archer GE, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrã¨S Dans Les Recherches Sur Le Cancer. 141: 101-22. PMID 8722422 DOI: 10.1007/978-3-642-79952-5_7  0.373
1996 Davis FG, Malinski N, Haenszel W, Chang J, Flannery J, Gershman S, Dibble R, Bigner DD. Primary brain tumor incidence rates in four United States regions, 1985-1989: a pilot study. Neuroepidemiology. 15: 103-12. PMID 8684582 DOI: 10.1159/000109895  0.38
1996 McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 35: 69-80. PMID 8641929 DOI: 10.1016/S0360-3016(96)85013-9  0.482
1996 McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS. Production and characterization of two ependymoma xenografts. Journal of Neuropathology and Experimental Neurology. 55: 540-8. PMID 8627345 DOI: 10.1097/00005072-199605000-00007  0.521
1996 McCowage G, Tien R, McLendon R, Felsberg G, Fuchs H, Graham ML, Kurtzberg J, Moghrabi A, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Robertson PL, Colvin OM, Golembe B, ... Bigner DD, et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Medical and Pediatric Oncology. 27: 32-9. PMID 8614389 DOI: 10.1002/(Sici)1096-911X(199607)27:1<32::Aid-Mpo7>3.0.Co;2-V  0.471
1996 Ashley DM, Longee D, Tien R, Fuchs H, Graham ML, Kurtzberg J, Casey J, Olson J, Meier L, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Colvin OM, Pipas JM, ... ... Bigner DD, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Medical and Pediatric Oncology. 26: 387-92. PMID 8614374 DOI: 10.1002/(Sici)1096-911X(199606)26:6<387::Aid-Mpo3>3.0.Co;2-D  0.535
1995 Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE, Pastan IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1545-55. PMID 9815955  0.479
1995 Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 15: 244-56. PMID 8586461 DOI: 10.1002/Glia.440150306  0.582
1995 Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH. Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology. 24: 39-45. PMID 8523074 DOI: 10.1007/Bf01052657  0.558
1995 Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. Journal of Neuro-Oncology. 24: 109-22. PMID 8523067 DOI: 10.1007/Bf01052668  0.575
1995 Friedman HS, Bigner SH, Bigner DD. Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). Journal of Neuro-Oncology. 24: 103-8. PMID 8523066 DOI: 10.1007/Bf01052667  0.329
1995 Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW. A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery. 36: 976-84; discussion 9. PMID 7791991 DOI: 10.1227/00006123-199505000-00014  0.581
1995 Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proceedings of the National Academy of Sciences of the United States of America. 92: 2765-9. PMID 7708720 DOI: 10.1073/Pnas.92.7.2765  0.541
1995 Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Research. 55: 4375-82. PMID 7671250  0.305
1995 Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD. Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Research. 55: 3803-9. PMID 7641197  0.428
1994 Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 34: 171-4. PMID 8194169 DOI: 10.1007/Bf00685936  0.315
1994 Batra SK, Niswonger ML, Wikstrand CJ, Pegram CN, Zalutsky MR, Morrison SL, Bigner DD. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma. 13: 87-97. PMID 8050781 DOI: 10.1089/Hyb.1994.13.87  0.313
1994 McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathology (Zurich, Switzerland). 4: 221-8. PMID 7952263 DOI: 10.1111/J.1750-3639.1994.Tb00837.X  0.478
1994 Wikstrand CJ, Fredman P, McLendon RR, Svennerholm L, Bigner DD. Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro Molecular and Chemical Neuropathology. 21: 129-138. PMID 7522005 DOI: 10.1007/Bf02815347  0.379
1994 He X, Archer GE, Wikstrand CJ, Morrison SL, Zalutsky MR, Bigner DD, Batra SK. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin Journal of Neuroimmunology. 52: 127-137. PMID 7518471 DOI: 10.1016/0165-5728(94)90106-6  0.348
1994 Wikstrand CJ, Fredman P, Svennerholm L, Bigner DD. Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Progress in Brain Research. 101: 213-23. PMID 7518092 DOI: 10.1016/S0079-6123(08)61951-2  0.393
1993 Schold SC, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 77-83. PMID 8418246 DOI: 10.1200/Jco.1993.11.1.77  0.534
1993 Garg S, Garg PK, Zhao XG, Friedman HS, Bigner DD, Zalutsky MR. Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Nuclear Medicine and Biology. 20: 835-42. PMID 8241995 DOI: 10.1016/0969-8051(93)90149-O  0.357
1993 Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold SC. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Journal of the National Cancer Institute. 84: 1926-31. PMID 1334154 DOI: 10.1093/Jnci/84.24.1926  0.324
1993 McLENDON RE, BATRA SK, FRIEDMAN HS, RASHEED B, BIGNER DD, BIGNER SH. EXPRESSION OF C-MYC IN MEDULLOBLASTOMA XENOGRAFTS Journal of Neuropathology and Experimental Neurology. 52: 267. DOI: 10.1097/00005072-199305000-00030  0.457
1993 Schold S, Zalutsky M, Coleman R, Glantz M, Friedman A, Jaszczak R, Bigner S, Bigner D. Distribution and Dosimetry of I-123-Labeled Monoclonal Antibody 81C6 in Patients with Anaplastic Glioma Investigative Radiology. 28: 488-496. DOI: 10.1097/00004424-199306000-00003  0.387
1992 Halperin EC, Brizel DM, Honore G, Sontag MR, Griffith OW, Bigner DD, Friedman HS. The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. International Journal of Radiation Oncology, Biology, Physics. 24: 103-9. PMID 1512145 DOI: 10.1016/0360-3016(92)91028-L  0.356
1992 Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, Kemshead JT. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. International Journal of Cancer. 52: 38-43. PMID 1500225 DOI: 10.1002/Ijc.2910520109  0.3
1992 Schuster JM, Bigner DD. Immunotherapy and monoclonal antibody therapies. Current Opinion in Oncology. 4: 547-52. PMID 1498162 DOI: 10.1097/00001622-199206000-00020  0.33
1992 Rasheed BK, Fuller GN, Friedman AH, Bigner DD, Bigner SH. Loss of heterozygosity for 10q loci in human gliomas. Genes, Chromosomes & Cancer. 5: 75-82. PMID 1384665 DOI: 10.1002/Gcc.2870050111  0.343
1992 Wikstrand CJ, Fredman P, Svennerholm L, Humphrey PA, Bigner SH, Bigner DD. Monoclonal antibodies to malignant human gliomas. Molecular and Chemical Neuropathology / Sponsored by the International Society For Neurochemistry and the World Federation of Neurology and Research Groups On Neurochemistry and Cerebrospinal Fluid. 17: 137-46. PMID 1384525 DOI: 10.1007/Bf03159988  0.409
1991 Friedman HS, Oakes WJ, Bigner SH, Wikstrand CJ, Bigner DD. Medulloblastoma: tumor biological and clinical perspectives. Journal of Neuro-Oncology. 11: 1-15. PMID 1919642 DOI: 10.1007/Bf00166992  0.374
1991 Ostrowski LE, von Wronski MA, Bigner SH, Rasheed A, Schold SC, Brent TP, Mitra S, Bigner DD. Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines. Carcinogenesis. 12: 1739-44. PMID 1893534 DOI: 10.1093/Carcin/12.9.1739  0.367
1991 Gottfries J, Percy AK, Månsson JE, Fredman P, Wikstrand CJ, Friedman HS, Bigner DD, Svennerholm L. Glycolipids and glycosyltransferases in permanent cell lines established from human medulloblastomas. Biochimica Et Biophysica Acta. 1081: 253-61. PMID 1825612 DOI: 10.1016/0005-2760(91)90279-Q  0.338
1991 Wikstrand CJ, He XM, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. Journal of Neuropathology and Experimental Neurology. 50: 756-69. PMID 1748882 DOI: 10.1097/00005072-199111000-00007  0.383
1991 Humphrey PA, Gangarosa LM, Wong AJ, Archer GE, Lund-Johansen M, Bjerkvig R, Laerum OD, Friedman HS, Bigner DD. Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function Biochemical and Biophysical Research Communications. 178: 1413-1420. PMID 1678600 DOI: 10.1016/0006-291X(91)91051-D  0.303
1991 Longee DC, Wikstrand CJ, MÃ¥nsson JE, He X, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD. Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas. Acta Neuropathologica. 82: 45-54. PMID 1659106 DOI: 10.1007/Bf00310922  0.399
1991 Schuster JM, Friedman HS, Bigner DD. Therapeutic Analysis of in Vitro and in Vivo Brain Tumor Models Neurologic Clinics. 9: 375-382. DOI: 10.1016/S0733-8619(18)30291-3  0.41
1990 He X, Wikstrand CJ, Fredman P, Månsson JE, Svennerholm L, Bigner DD. GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathologica. 79: 317-25. PMID 2609939 DOI: 10.1007/Bf00294668  0.375
1990 Fredman P, MÃ¥nsson JE, Bigner SH, Wikstrand CJ, Bigner DD, Svennerholm L. Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats. Biochimica Et Biophysica Acta. 1045: 239-44. PMID 2386796 DOI: 10.1016/0005-2760(90)90126-I  0.309
1990 Oakes WJ, Friedman HS, Bigner SH, Bullock NH, Bigner DD. Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note. Journal of Neurosurgery. 72: 821-3. PMID 2324807 DOI: 10.3171/Jns.1990.72.5.0821  0.396
1990 Ibayashi N, Herman MM, Boyd JC, Caccamo DV, Friedman HS, Bigner DD, Rubinstein LJ. Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study. Neuropathology and Applied Neurobiology. 16: 27-37. PMID 2320202 DOI: 10.1111/J.1365-2990.1990.Tb00929.X  0.313
1990 Lippitz BE, Halperin EC, Griffith OW, Colvin OM, Honore G, Ostertag CB, Bigner DD, Friedman HS. L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. Neurosurgery. 26: 255-60. PMID 2308673 DOI: 10.1097/00006123-199002000-00012  0.335
1990 Davidsson P, Fredman P, Holst HV, Wikstrand CJ, He X, Bigner DD, Svennerholm L. Circulating glycoconjugates in CSF of meningioma patients. Acta Neurologica Scandinavica. 82: 203-208. PMID 2270748 DOI: 10.1111/J.1600-0404.1990.Tb04489.X  0.364
1990 Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genetics and Cytogenetics. 47: 141-54. PMID 2192793 DOI: 10.1016/0165-4608(90)90024-5  0.352
1990 Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 87: 4207-11. PMID 1693434 DOI: 10.1073/Pnas.87.11.4207  0.317
1990 Longee DC, He X, Wikstrand CJ, Fuller GN, Bigner SH, Fredman P, Månsson J-, Svennerholm L, Bigner DD. EXPRESSION OF GD2 BY TUMOR CELL LINES OF NEUROECTODERMAL ORIGIN AND HUMAN GLIOMAS AS DEFINED BY AN EPITOPE-DEFINED ANTI-GD2 MONOCLONAL ANTIBODY Journal of Neuropathology and Experimental Neurology. 49: 320. DOI: 10.1097/00005072-199005000-00184  0.386
1989 Colapinto EV, Lee YS, Humphrey PA, Zalutsky MR, Friedman HS, Bullard DE, Bigner DD. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice. British Journal of Neurosurgery. 2: 179-91. PMID 3267302 DOI: 10.3109/02688698808992668  0.301
1989 Schold SC, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. Journal of Neurosurgery. 70: 573-7. PMID 2926498 DOI: 10.3171/Jns.1989.70.4.0573  0.368
1989 Bigner SH, Schold SC, Friedman HS, Mark J, Bigner DD. Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. Cancer Genetics and Cytogenetics. 40: 111-20. PMID 2758393 DOI: 10.1016/0165-4608(89)90152-0  0.397
1989 He XM, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD. Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. Journal of Neuropathology and Experimental Neurology. 48: 48-68. PMID 2535715 DOI: 10.1097/00005072-198901000-00005  0.332
1989 Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proceedings of the National Academy of Sciences of the United States of America. 86: 7149-53. PMID 2476813 DOI: 10.1073/Pnas.86.18.7149  0.307
1989 Vrionis FD, Wikstrand CJ, Bigner DD. Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. Annals of the New York Academy of Sciences. 540: 64-77. PMID 2462837 DOI: 10.1111/J.1749-6632.1988.Tb27052.X  0.303
1989 Fuchs HE, Archer GE, Schuster JM, Colvin OM, Bigner SH, Muhlbaier LH, Friedman HS, Bigner DD. A NUDE RAT MODEL OF LEPTOMENINGEAL TUMOR DISSEMINATION (LTD) OF HUMAN MEDULLOBLASTOMA Journal of Neuropathology and Experimental Neurology. 48: 356. DOI: 10.1097/00005072-198905000-00173  0.35
1989 Vrionis FD, Wikstrand CJ, Fredman P, Mansson J-, Svennerholm L, Bigner DD. DETERMINATION OF GM2 IN CULTURED HUMAN GLIOMA, MEDULLOBLASTOMA AND NEUROBLASTOMA CELLS WITH EPITOPE-DEFINED MONOCLONAL ANTIBODIES (MAbs) Journal of Neuropathology and Experimental Neurology. 48: 356. DOI: 10.1097/00005072-198905000-00171  0.309
1989 He X, Wikstrand CJ, Fredman P, Månsson J-, Svennerholm L, Bigner DD. DISTRIBUTION OF GANGLIOSIDE GD3 IN CULTURED HUMAN TUMOR CELLS OF NEUROECTODERMAL ORIGIN AS DEFINED BY ANTI-GD3 MONOCLONAL ANTIBODIES Journal of Neuropathology and Experimental Neurology. 48: 305. DOI: 10.1097/00005072-198905000-00018  0.357
1989 Cope D, Slade S, Dewhirst M, Frinman H, Bigner D, Oleson J, Zalutsky M. Local hyperthermia at 420c enhances monoclonal antibody fragment uptake in tumor International Journal of Radiation Oncology*Biology*Physics. 17: 119-120. DOI: 10.1016/0360-3016(89)90639-1  0.351
1988 Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genetics and Cytogenetics. 30: 91-101. PMID 3422050 DOI: 10.1016/0165-4608(88)90096-9  0.354
1988 Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. Journal of Neuropathology and Experimental Neurology. 47: 191-205. PMID 3367154 DOI: 10.1097/00005072-198805000-00001  0.581
1988 Werner MH, Humphrey PA, Bigner DD, Bigner SH. Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathologica. 77: 196-201. PMID 3265834 DOI: 10.1007/Bf00687431  0.341
1988 Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochemical Pharmacology. 37: 4313-7. PMID 3196356 DOI: 10.1016/0006-2952(88)90612-0  0.362
1987 Warnke PC, Molnar P, Bigner DD, Heistad DH, Groothuis DR. Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. Neurology. 37: 1870-3. PMID 3683879 DOI: 10.1212/Wnl.37.12.1870  0.347
1987 el-Hennawi Y, Gillespie GY, Mahaley MS, Bigner DD. Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report. Journal of Neuro-Oncology. 5: 161-2. PMID 3668611 DOI: 10.1007/Bf02571304  0.342
1987 McComb RD, Moul JM, Bigner DD. Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. Journal of Neuropathology and Experimental Neurology. 46: 623-33. PMID 3655835 DOI: 10.1097/00005072-198711000-00002  0.341
1987 Biegel JA, Leslie DS, Bigner DD, Bigner SH. Hydroxyurea synchronization increases mitotic yield in human glioma cell lines. Acta Neuropathologica. 73: 309-12. PMID 3618122 DOI: 10.1007/Bf00686628  0.364
1987 Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, de Tribolet N, Bullard DE, Zalutsky MR, Bigner DD. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. Journal of Neuroimmunology. 15: 37-56. PMID 3571486 DOI: 10.1016/0165-5728(87)90005-1  0.559
1987 de Ridder LI, Laerum OD, Mørk SJ, Bigner DD. Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice. Acta Neuropathologica. 72: 207-13. PMID 3564901 DOI: 10.1007/Bf00691091  0.318
1987 Bigner SH, Wong AJ, Mark J, Muhlbaier LH, Kinzler KW, Vogelstein B, Bigner DD. Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genetics and Cytogenetics. 29: 165-70. PMID 3478127 DOI: 10.1016/0165-4608(87)90045-8  0.397
1987 Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences of the United States of America. 84: 6899-903. PMID 3477813 DOI: 10.1073/Pnas.84.19.6899  0.352
1987 Bigner SH, Mark J, Bigner DD. Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro. Cancer Genetics and Cytogenetics. 24: 163-76. PMID 3466669 DOI: 10.1016/0165-4608(87)90094-X  0.308
1987 El-Hennawi Y, Gillespie GY, Varia MA, Watkins P, Mahaley MS, Bigner DD. Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas. Journal of Neuro-Oncology. 4: 309-13. PMID 3031229 DOI: 10.1007/Bf00150620  0.358
1987 Britt RH, Lyons BE, Enzmann DR, Saxer EL, Bigner SH, Bigner DD. Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors. Journal of Neuro-Oncology. 4: 243-68. PMID 3031228 DOI: 10.1007/Bf00150616  0.359
1987 Lee YS, Wikstrand CJ, Bigner DD. Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. Journal of Neuroimmunology. 13: 183-202. PMID 2430997 DOI: 10.1016/0165-5728(86)90064-0  0.337
1987 McLendon RE, Burger PC, Bigner SH, Bigner DD. PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASMS IN FISCHER-344 RATS RECEIVING CHRONIC LIFETIME EXPOSURE TO ACRYLONITRILE (ACN) Journal of Neuropathology and Experimental Neurology. 46: 389. DOI: 10.1097/00005072-198705000-00178  0.555
1987 Bigner SH, Burger PC, Wong AJ, Kinzier KK, Hamilton SR, Vogelstein B, Bigner DD. MORPHOLOGIC CHARACTERISTICS OF MALIGNANT HUMAN GLIOMAS (MHG) WITH GENE AMPLIFICATION Journal of Neuropathology and Experimental Neurology. 46: 373. DOI: 10.1097/00005072-198705000-00130  0.477
1987 Vriesendorp FJ, Peagram C, Bigner DD, Groothuis DR. Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats. Journal of the National Cancer Institute. 79: 123-130. DOI: 10.1093/Jnci/79.1.123  0.367
1986 Bigner DD, Bigner SH, Burger PC, Shelburne JD, Friedman HS. Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 24: 129-37. PMID 3957160 DOI: 10.1016/0278-6915(86)90347-9  0.456
1986 Bullard DE, Adams CJ, Coleman RE, Bigner DD. In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. Journal of Neurosurgery. 64: 257-62. PMID 3944636 DOI: 10.3171/Jns.1986.64.2.0257  0.403
1986 McLendon RE, Burger PC, Pegram CN, Eng LF, Bigner DD. The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues. Journal of Neuropathology and Experimental Neurology. 45: 692-703. PMID 3534145 DOI: 10.1097/00005072-198611000-00007  0.603
1986 Lee YS, Bigner SH, Eng LF, Molnar P, Kuruvilla A, Groothuis DR, Bigner DD. A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma. Journal of Neuropathology and Experimental Neurology. 45: 704-20. PMID 3021915 DOI: 10.1097/00005072-198611000-00008  0.407
1986 Bigner SH, Mark J, Bullard DE, Mahaley MS, Bigner DD. Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genetics and Cytogenetics. 22: 121-35. PMID 3011240 DOI: 10.1016/0165-4608(86)90172-X  0.345
1986 Lee YS, Matthews TJ, Pizzo S, Abernethy JL, Bigner DD. Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies Journal of Neuroimmunology. 13: 203-216. PMID 2430998 DOI: 10.1016/0165-5728(86)90065-2  0.519
1986 Wikstrand CJ, Humphrey PA, Lee YS, Coleman RE, Zalutsky M, Bigner DD, Bullard DE. Specific Imaging of Human Brain Tumor Xenografts Utilizing Radiolabelled Monoclonal Antibodies (MAbs) Nuklearmedizin. 25: 210-215. DOI: 10.1055/S-0038-1624344  0.384
1986 Clifford Schold S, Walker MD, Wilson CB, Bigner DD. Summary of the sixth international conference on brain tumor research and therapy Journal of Neuro-Oncology. 4: 3-4. DOI: 10.1007/Bf02157995  0.37
1985 Bourdon MA, Matthews TJ, Pizzo SV, Bigner DD. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein Journal of Cellular Biochemistry. 28: 183-195. PMID 4066774 DOI: 10.1002/Jcb.240280302  0.534
1985 Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC, Bigner DD. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. Journal of Neuropathology and Experimental Neurology. 44: 592-605. PMID 4056828 DOI: 10.1097/00005072-198511000-00005  0.515
1985 McComb RD, Bigner DD. Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. Journal of Neuro-Oncology. 3: 181-6. PMID 4031975 DOI: 10.1007/Bf02228895  0.386
1985 Bullard DE, Thomas DG, Darling JL, Wikstrand CJ, Diengdoh JV, Barnard RO, Bodmer JG, Bigner DD. A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. British Journal of Cancer. 51: 283-9. PMID 3966985 DOI: 10.1038/Bjc.1985.41  0.337
1985 McComb RD, Bigner DD. Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems. Journal of Neuropathology and Experimental Neurology. 44: 242-53. PMID 3886847 DOI: 10.1097/00005072-198505000-00003  0.343
1985 Bigner SH, Mark J, Schold SC, Eng LF, Bigner DD. A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line. Cancer Genetics and Cytogenetics. 18: 141-53. PMID 3840409 DOI: 10.1016/0165-4608(85)90064-0  0.366
1985 Panther LA, Baumbach GL, Bigner DD, Piegors D, Groothuis DR, Heistad DD. Vasoactive drugs produce selective changes in flow to experimental brain tumors. Annals of Neurology. 18: 712-5. PMID 3002239 DOI: 10.1002/Ana.410180614  0.326
1985 Britt RH, Lyons BE, Eng LF, Bigner SH, Bigner DD. Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs. Journal of Neuro-Oncology. 3: 53-9. PMID 2987428 DOI: 10.1007/Bf00165172  0.374
1985 Campbell GL, Bartel R, Freidman HS, Bigner DD. Effect of glutamate analogues on brain tumor cell lines. Journal of Neurochemistry. 45: 1186-92. PMID 2863331 DOI: 10.1111/J.1471-4159.1985.Tb05540.X  0.309
1985 Wikstrand CJ, Grahmann FC, McComb RD, Bigner DD. Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies. Journal of Neuropathology and Experimental Neurology. 44: 229-41. PMID 2580959 DOI: 10.1097/00005072-198505000-00002  0.36
1985 Bullard DE, Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. Journal of Neurosurgery. 63: 2-16. PMID 2409248 DOI: 10.3171/Jns.1985.63.1.0002  0.412
1985 McLendon RE, Burger PC, Eng LF, Wikstrand CJ, Pegram CN, Bigner DD. PRODUCTION AND CHARACTERIZATION OF 3 MONOCLONAL ANTIBODIES (MAs) TO GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) Journal of Neuropathology and Experimental Neurology. 44: 331. DOI: 10.1097/00005072-198505000-00083  0.566
1985 Lee Y, Bigner DD. Aspects of Immunobiology and Immunotherapy and Uses of Monoclonal Antibodies and Biologic Immune Modifiers in Human Gliomas Neurologic Clinics. 3: 901-917. DOI: 10.1016/S0733-8619(18)31221-0  0.439
1985 Blasberg R, Nakagawa H, Bourdon M, Groothuis D, Patlak C, Bigner D. Monoclonal antibody transport across tumor and systemic tissue Journal of Neuroimmunology. 10: 180. DOI: 10.1016/0165-5728(85)90023-2  0.33
1984 Bullard DE, Saris SC, Bigner DD. Carotid artery injections in 40- to 99-g Fischer rats: technical note and evaluation of blood flow by various injection techniques. Neurosurgery. 14: 406-11. PMID 6728142 DOI: 10.1227/00006123-198404000-00003  0.338
1984 Saris SC, Bigner SH, Bigner DD. Intracerebral transplantation of a human glioma line in immunosuppressed rats. Journal of Neurosurgery. 60: 582-8. PMID 6699702 DOI: 10.3171/Jns.1984.60.3.0582  0.406
1984 Bigner SH, Mark J, Mahaley MS, Bigner DD. Patterns of the early, gross chromosomal changes in malignant human gliomas. Hereditas. 101: 103-13. PMID 6490389 DOI: 10.1111/J.1601-5223.1984.Tb00455.X  0.322
1984 Bourdon MA, Coleman RE, Bigner DD. The potential of monoclonal antibodies as carriers of radiation and drugs for immunodetection and therapy of brain tumors. Progress in Experimental Tumor Research. 28: 79-101. PMID 6484206 DOI: 10.1159/000408239  0.35
1984 Wikstrand CJ, Bigner SH, Bigner DD. Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG. Journal of Neuroimmunology. 6: 169-86. PMID 6373821 DOI: 10.1016/0165-5728(84)90004-3  0.379
1984 Bigner SH, Burger PC, Mark J, Bullard DE, Bigner DD. 128 RELATIONSHIP BETWEEN KARYOTYPE AND HISTOLOGIC PARAMETERS OF MALIGNANT HUMAN GLIOMAS (MHG) Journal of Neuropathology and Experimental Neurology. 43: 335. DOI: 10.1097/00005072-198405000-00134  0.465
1984 Lee YS, Pegram CN, Bigner DD. 25 GLIOMA-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODIES (MAs) AGAINST AN AVIAN SARCOMA VIRUS (ASV)-INDUCED RAT ASTROCYTOMA CELL LINE Journal of Neuropathology and Experimental Neurology. 43: 301. DOI: 10.1097/00005072-198405000-00034  0.309
1984 Bourdon MA, Matthews TJ, Pizzo SV, Bigner DD. 24 IMMUNOCHEMICAL AND BIOCHEMICAL ANALYSIS OF THE HUMAN GLIOMA EXTRACELLULAR MATRIX GLYCOPROTEIN (GMEM) Journal of Neuropathology and Experimental Neurology. 43: 301. DOI: 10.1097/00005072-198405000-00033  0.459
1983 Friedman HS, Bigner SH, McComb RD, Schold SC, Pasternak JF, Groothuis DR, Bigner DD. A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice. Journal of Neuropathology and Experimental Neurology. 42: 485-503. PMID 6886736 DOI: 10.1097/00005072-198309000-00001  0.334
1983 Mahaley MS, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM. Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study. Journal of Neurosurgery. 59: 201-7. PMID 6864286 DOI: 10.3171/Jns.1983.59.2.0201  0.379
1983 Bigbee JW, Bigner DD, Eng LF. Glial fibrillary acidic protein synthesized in vitro using messenger RNA from a human glioma cell line. Journal of Neuropathology and Experimental Neurology. 42: 80-6. PMID 6822846 DOI: 10.1097/00005072-198301000-00007  0.337
1983 Bigbee JW, Bigner DD, Pegram C, Eng LF. Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor. Journal of Neurochemistry. 40: 460-7. PMID 6822832 DOI: 10.1111/J.1471-4159.1983.Tb11305.X  0.335
1983 Schold SC, Rawlings CE, Bigner SH, Bigner DD. Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. Neurosurgery. 12: 672-7. PMID 6683794 DOI: 10.1227/00006123-198306000-00014  0.421
1983 Schold SC, Bullard DE, Bigner SH, Jones TR, Bigner DD. Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice. Journal of Neuro-Oncology. 1: 5-14. PMID 6678306 DOI: 10.1007/Bf00153635  0.406
1983 Mahaley MS, Aronin PA, Michael AJ, Bigner D. Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation. Surgical Neurology. 19: 453-5. PMID 6302929 DOI: 10.1016/0090-3019(83)90145-3  0.336
1983 Molnar P, Blasberg RG, Groothuis D, Bigner D, Fenstermacher JD. Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors. Neurology. 33: 702-11. PMID 6302563 DOI: 10.1212/Wnl.33.6.702  0.382
1983 Groothuis D, Blasberg RG, Molnar P, Bigner D, Fenstermacher JD. Regional blood flow in avian sarcoma virus (ASV)-induced brain tumors. Neurology. 33: 686-96. PMID 6302562 DOI: 10.1212/Wnl.33.6.686  0.375
1983 McComb RD, Wikstrand CJ, Bourdon MA, Bigner SH, Bigner DD. 10 ANTIGENIC HETEROGENEITY OF HUMAN MALIGNANT GLIOMAS (MGs) DEMONSTRATED BY REACTIVITY WITH 10 MONOCLONAL ANTIBODIES (MCAs) Journal of Neuropathology and Experimental Neurology. 42: 308. DOI: 10.1097/00005072-198305000-00020  0.319
1982 Wikstrand CJ, Bigner DD. Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. Journal of Neuroimmunology. 1: 249-60. PMID 7334081 DOI: 10.1016/0165-5728(81)90029-1  0.326
1982 Tribolet Nd, Bigner DD. Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors Journal of Neuroimmunology. 3: 237-243. PMID 7142382 DOI: 10.1016/0165-5728(82)90026-1  0.387
1982 Groothuis DR, Fischer JM, Lapin G, Bigner DD, Vick NA. Permeability of different experimental brain tumor models to horseradish peroxidase. Journal of Neuropathology and Experimental Neurology. 41: 164-85. PMID 7062086 DOI: 10.1097/00005072-198203000-00006  0.406
1982 McComb RD, Jones TR, Pizzo SV, Bigner DD. Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis. Acta Neuropathologica. 56: 207-13. PMID 6803512 DOI: 10.1007/Bf00690637  0.522
1982 McComb RD, Jones TR, Pizzo SV, Bigner DD. Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 30: 371-7. PMID 6801111 DOI: 10.1177/30.4.6801111  0.476
1982 Wikstrand CJ, Bourdon MA, Pegram CN, Bigner DD. Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. Journal of Neuroimmunology. 3: 43-62. PMID 6284796 DOI: 10.1016/0165-5728(82)90017-0  0.389
1982 Strauss MM, Bigner SH, Bigner DD. Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors. Journal of Neuroimmunology. 2: 283-94. PMID 6282929 DOI: 10.1016/0165-5728(82)90061-3  0.369
1982 MCCOMB RD, JONES TR, PIZZO SV, BIGNER DD. Immunohistochemical Detection of Factor VIII/von Willebrand Factor in Hyperplastic Endothelial Cells in Glioblastoma Multiforme and Mixed Glioma-Sarcoma Journal of Neuropathology and Experimental Neurology. 41: 497. DOI: 10.1097/00005072-198209000-00001  0.503
1982 Bourdon MA, Wikstrand CJ, Coleman RE, Bigner DD. SPECIFICITY AND TUMOR LOCALIZATION OF A MONOCLONAL ANTIBODY (MA) DEFINING A HUMAN GLIOMA ASSOCIATED EXTRACELLULAR MATRIX ANTIGEN Journal of Neuropathology and Experimental Neurology. 41: 367. DOI: 10.1097/00005072-198205000-00088  0.361
1981 Serano RD, Pegram CN, Bigner DD. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathologica. 51: 53-64. PMID 7435141 DOI: 10.1007/Bf00688850  0.313
1981 Bullard DE, Schold SC, Bigner SH, Bigner DD. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. Journal of Neuropathology and Experimental Neurology. 40: 410-27. PMID 7252525 DOI: 10.1097/00005072-198107000-00005  0.428
1981 Bigner SH, Bullard DE, Pegram CN, Wikstrand CJ, Bigner DD. Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. Journal of Neuropathology and Experimental Neurology. 40: 390-409. PMID 7252524 DOI: 10.1097/00005072-198107000-00004  0.307
1981 Bullard DE, Bigner SH, Bigner DD. The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3':5'-cyclic monophosphate. Journal of Neuropathology and Experimental Neurology. 40: 230-46. PMID 6260908 DOI: 10.1097/00005072-198105000-00002  0.314
1981 Bigner DD, Bigner SH, Pontén J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ. Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. Journal of Neuropathology and Experimental Neurology. 40: 201-29. PMID 6260907 DOI: 10.1097/00005072-198105000-00001  0.33
1981 Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. Journal of Neurosurgery. 55: 32-42. PMID 6165811 DOI: 10.3171/Jns.1981.55.1.0032  0.39
1981 Bigner DD. Biology of Gliomas Neurosurgery. 9: 320-326. DOI: 10.1097/00006123-198109000-00020  0.313
1981 McComb RD, Jones TR, Pizzo SV, Bigner DD. 113 IMMUNOPEROXIDASE DETECTION OF FACTOR VIII/VON WILLEBRAND FACTOR (FVIII/vWF) IN GLIOBLASTOMA MULTIFORME (GBM), MIXED GLIOMA-SARCOMA (GS), HEMAN-GIOBLASTOMA (HBL), AND MENINGEAL HEMANGIOPERICYTOMA (HP) Journal of Neuropathology and Experimental Neurology. 40: 336. DOI: 10.1097/00005072-198105000-00120  0.471
1980 Groothuis DR, Fischer JM, Vick NA, Bigner DD. Experimental gliomas: an autoradiographic study of the endothelial component. Neurology. 30: 297-301. PMID 6244516 DOI: 10.1212/Wnl.30.3.297  0.364
1979 Bullard DE, Bigner DD. Heterotransplantation of human craniopharyngiomas in athymic "nude" mice. Neurosurgery. 4: 308-14. PMID 450229 DOI: 10.1227/00006123-197904000-00006  0.304
1979 Sylvia AL, Somjen GG, Bigner DD, Rosenthal M. Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo. Journal of Neurochemistry. 32: 1371-7. PMID 220382 DOI: 10.1111/J.1471-4159.1979.Tb11074.X  0.35
1979 Jones TR, Kao KJ, Pizzo SV, Bigner DD. FACTOR VIII-A MARKER OF ENDOTHELIAL CELLS IN NORMAL BRAIN AND GLIOMAS Journal of Neuropathology and Experimental Neurology. 38: 324. DOI: 10.1097/00005072-197905000-00080  0.493
1979 Bullard DE, Bigner DD. THE USE OF ATHYMIC ‘NUDE’ MICE FOR THE IN VIVO STUDY OF HUMAN NERVOUS SYSTEM TUMORS Journal of Neuropathology and Experimental Neurology. 38: 306. DOI: 10.1097/00005072-197905000-00024  0.351
1978 Copeland DD, Bigner DD. Glial-mesenchymal tropism of in vivo avian sarcoma virus neuro-oncogenesis in rats. Acta Neuropathologica. 41: 23-5. PMID 205079 DOI: 10.1007/Bf00689552  0.317
1978 Bigner DD, Wikstrand CJ. FETAL AND ADULT BRAIN-ASSOCIATED SURFACE ANTIGENS OF HUMAN GLIOMA (HGL) CELL LINES AND CLONES Journal of Neuropathology and Experimental Neurology. 37: 591. DOI: 10.1097/00005072-197809000-00071  0.306
1977 Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. Archives of Neurology. 34: 523-6. PMID 889492 DOI: 10.1001/Archneur.1977.00500210025002  0.392
1977 Vick NA, Lin MJ, Bigner DD. The role of the subependymal plate in glial tumorigenesis. Acta Neuropathologica. 40: 63-71. PMID 199034 DOI: 10.1007/Bf00688574  0.349
1977 Mahaley MS, Gentry RE, Bigner DD. Immunobiology of primary intracranial tumors. Journal of Neurosurgery. 47: 35-43. PMID 194022 DOI: 10.3171/Jns.1977.47.1.0035  0.386
1977 Copeland DD, Bigner DD. The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats. Acta Neuropathologica. 38: 1-6. PMID 193346 DOI: 10.1007/Bf00691268  0.351
1977 Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. Journal of Neurosurgery. 46: 467-76. PMID 191575 DOI: 10.3171/Jns.1977.46.4.0467  0.387
1977 Bigner DD, Wilson CB. Workshop on cancer of the brain Journal of Neurosurgery. 47: 923-932. DOI: 10.3171/Jns.1977.47.6.0923  0.345
1976 Adams DO, Gilbert RW, Bigner DD. Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors. Journal of the National Cancer Institute. 56: 1119-23. PMID 186622 DOI: 10.1093/Jnci/56.6.1119  0.385
1975 Cloyd MW, Burger PC, Bigner DD. R-type virus-like particles in avian sarcoma virus-induced rat central nervous system tumors. Journal of the National Cancer Institute. 54: 1479-82. PMID 166194 DOI: 10.1093/Jnci/54.6.1479  0.479
1975 Copeland DD, Vogel FS, Bigner DD. The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. Journal of Neuropathology and Experimental Neurology. 34: 340-58. PMID 166146  0.459
Show low-probability matches.